BSX Stock Price Today (April 2026) — Boston Scientific Corporation Analysis & Key Metrics 2026-04-15
Boston Scientific Corporation (BSX) is trading at $63.42, down 0.63% today (as of April 2026). The stock continues to show pressure below major moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $101.25 (59.6% upside).
- Volatility remains elevated (37.39% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (15.90% YoY) alongside significant competitive pressures.
BSX Stock Analysis: Key Metrics & Valuation (April 2026)
Concise, actionable data for investors
Boston Scientific Corporation - Historical Price & Volume
Market Cap
Enterprise Value: $103.46B
P/E Ratio
Forward P/E: 16.07
Revenue Growth
Year over Year
Analyst Target
+59.6% upside potential
Key Investor Questions About BSX
What investors need to know before buying
Based on current market data, BSX presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 46.45)
- Fundamentals say: Caution warranted (high leverage concerns)
BSX's growth trajectory depends on its ability to expand within the Medical Devices sector while managing margin pressures.
- Future growth will depend on performance in core Medical Devices operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for BSX investors include debt exposure and competitive dynamics in the Medical Devices industry.
- $11.97B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Medical Devices.
52-Week Trading Range
Over the past year, BSX stock traded between $61.25 and $109.50—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 37.39% annualized volatility and β=0.70, the stock exhibits low sensitivity to market moves—making BSX suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Intuitive Surgical Pre-Q1 Analysis: Buy, Hold or Sell the Stock Now?
Intuitive Surgical faces a key test as earnings near, with strong procedure growth and da Vinci 5 adoption offset by pricing pressure and valuation concerns.
Analysts Bullish on Boston Scientific (BSX) Amid Expectations for 30% YoY Growth in 2026
Boston Scientific Corporation (NYSE:BSX) is included in our list of the best low-risk high-reward stocks. As part of the firm’s Q1 preview for medical technology and life science tools firms, Evercore ISI analyst Vijay Kumar reduced the firm’s price target on Boston Scientific Corporation (NYSE:BSX) to $80 from $96 on April 6, 2026, while maintaining an “Outperform” […]
Boston Scientific plans $88.5M R&D expansion in Ireland
The device maker plans to invest 75 million euros into expanding the site, with a focus on cardiovascular innovation.
Revisiting Stock Picks Burlington Stores, Boston Scientific, Pinterest
FEATURE Looking back at previous stock picks can offer a valuable lens into how ideas evolve once they meet real market conditions. Some have played out as expected while others have taken unanticipated paths.
A Look At Boston Scientific (BSX) Valuation After The Penumbra Acquisition And Recent Shareholder Returns
Boston Scientific overview and recent trading context Boston Scientific (BSX) develops medical devices across MedSurg and Cardiovascular segments. Its shares have recently faced pressure, with negative returns over the month, past 3 months, year to date, and past year. See our latest analysis for Boston Scientific. The recent 1-day and 7-day share price returns of 1.24% and 3.28% sit against a 30-day share price return of 7.42% and a year-to-date share price return of 31.78%. The 1-year total...
Boston Scientific (BSX) Outperforms Broader Market: What You Need to Know
Boston Scientific (BSX) closed the most recent trading day at $64.61, moving +1.24% from the previous trading session.
Boston Scientific (BSX) Earnings Expected to Grow: Should You Buy?
Boston Scientific (BSX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AIP to acquire Avanos Medical in $1.27B go-private deal
Avanos Medical generated $701.2 million last year from sectors where it competes with Boston Scientific, Medtronic and Stryker.
Citi Reiterates Buy rating for Boston Scientific (BSX)
Boston Scientific Corp. (NYSE:BSX) is one of the 7 oversold stocks to buy with double-digit ROE growth. On April 7, Joanne Wuensch from Citi reduced the price target on Boston Scientific Corp. (NYSE:BSX) from $98 to $87 while maintaining a Buy rating on the stock. This implies an adjusted upside potential of more than 40% […]
Will Boston Scientific (BSX) Beat Estimates Again in Its Next Earnings Report?
Boston Scientific (BSX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Frequently Asked Questions
Common investor questions about Boston Scientific Corporation
Boston Scientific Corporation (BSX) is currently trading at $63.42. The RSI (14-day) is at 46.5, indicating neutral territory. Wall Street analysts have a consensus "strong_buy" recommendation. The mean analyst price target of $101.25 implies 59.6% upside from current levels. Volatility is moderate at 37.4% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Boston Scientific Corporation (BSX): The trailing P/E ratio is 32.38, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 16.07, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 0.68, below 1.0, which generally indicates the stock is undervalued relative to its growth rate. Price-to-Book is 3.84. Price-to-Sales is 4.65. Valuation should be compared to Medical Devices industry peers for context, as different sectors trade at different multiples.
Based on 32 analysts covering BSX, the consensus price target is $101.25. This represents a 59.6% upside from the current price of $63.42. The range spans from a low target of $83.00 to a high target of $124.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "strong_buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Boston Scientific Corporation (BSX) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Boston Scientific Corporation (BSX) investors include: 1. Moderate volatility (37.4% annualized)—price swings are notable. 2. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 3. Medical Devices sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Boston Scientific Corporation's (BSX) current debt and financial health profile: Total debt stands at $11.97B. The debt-to-equity ratio is 48.92, which is moderate and generally manageable for most companies. The current ratio is 1.62, indicating strong short-term liquidity. The quick ratio is 0.90. The company holds $1.96B in cash and equivalents. Free cash flow is positive at $3.24B, providing a cushion for debt servicing and shareholder returns.